Search results

Skip to results

Type

Type

Last updated

Last updated

Advice programme

Showing 1 result for haematopoiesis

  1. Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)

    NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .

    Medtech innovation briefing
    Published
    4 October 2022